{"id":3449,"date":"2025-09-03T13:13:58","date_gmt":"2025-09-03T16:13:58","guid":{"rendered":"https:\/\/overticeportal.com.br\/?p=3449"},"modified":"2025-09-03T13:14:19","modified_gmt":"2025-09-03T16:14:19","slug":"novo-medicamento-aprovado-pela-anvisa-revoluciona-tratamento-do-cancer-de-ovario-resistente","status":"publish","type":"post","link":"https:\/\/www.portalam9.com.br\/?p=3449","title":{"rendered":"Novo medicamento aprovado pela Anvisa revoluciona tratamento do c\u00e2ncer de ov\u00e1rio resistente"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">A Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria (Anvisa) aprovou o uso do mirvetuximabe soravtansina, conhecido comercialmente como Elahere, o primeiro medicamento espec\u00edfico para pacientes com c\u00e2ncer de ov\u00e1rio resistente \u00e0 quimioterapia \u00e0 base de platina. Essa condi\u00e7\u00e3o ocorre quando a doen\u00e7a retorna em at\u00e9 seis meses ap\u00f3s o tratamento padr\u00e3o, reduzindo significativamente as chances de resposta.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">O mirvetuximabe pertence \u00e0 classe dos conjugados anticorpo-f\u00e1rmaco (ADC). Ele combina um anticorpo direcionado ao receptor de folato alfa (FR\u03b1) \u2013 presente em cerca de um ter\u00e7o das pacientes \u2013 com uma carga quimioter\u00e1pica que destr\u00f3i seletivamente c\u00e9lulas tumorais, preservando em maior parte as c\u00e9lulas saud\u00e1veis.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Resultados de estudo cl\u00ednico internacional<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">A aprova\u00e7\u00e3o se baseou em um estudo de fase 3 com mais de 450 pacientes. Os resultados foram promissores:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>35% de redu\u00e7\u00e3o no risco de progress\u00e3o da doen\u00e7a em compara\u00e7\u00e3o \u00e0 quimioterapia convencional;<\/li>\n\n\n\n<li>Ganho em sobrevida global, com m\u00e9dia de 16,5 meses contra 12,7 meses no grupo de compara\u00e7\u00e3o;<\/li>\n\n\n\n<li>Taxa de resposta objetiva de 42%, contra apenas 16% na quimioterapia padr\u00e3o.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Os dados foram apresentados no congresso da ASCO (Sociedade Americana de Oncologia Cl\u00ednica) e publicados no New England Journal of Medicine.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Para que a terapia seja indicada, \u00e9 necess\u00e1rio o exame de imuno-histoqu\u00edmica, j\u00e1 dispon\u00edvel no Brasil, que identifica a presen\u00e7a do receptor FR\u03b1. Apenas pacientes com tumores positivos para esse biomarcador podem se beneficiar do novo tratamento.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\">Avan\u00e7o para pacientes no Brasil<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">O c\u00e2ncer de ov\u00e1rio \u00e9 um dos mais letais entre os ginecol\u00f3gicos, com cerca de 7,3 mil novos casos por ano no Brasil, segundo o\u00a0INCA. Como costuma ser diagnosticado em est\u00e1gio avan\u00e7ado, o tratamento \u00e9 desafiador e o risco de recidiva \u00e9 alto.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">A aprova\u00e7\u00e3o do Elahere representa um marco, j\u00e1 que h\u00e1 mais de oito anos n\u00e3o surgiam novas op\u00e7\u00f5es para esse perfil de pacientes. Ainda n\u00e3o est\u00e1 definida sua inclus\u00e3o no SUS ou no rol da ANS, mas especialistas destacam o potencial de mudar o cen\u00e1rio do c\u00e2ncer de ov\u00e1rio resistente.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><em>Fonte: Catraca Livre <strong>\/ <\/strong>Foto: \u00a0Marco Marca\/istock<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Mirvetuximabe soravtansina mostra ganho em sobrevida global e oferece esperan\u00e7a in\u00e9dita para pacientes no Brasil<\/p>\n","protected":false},"author":3,"featured_media":3450,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[51],"tags":[],"class_list":["post-3449","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Novo medicamento aprovado pela Anvisa revoluciona tratamento do c\u00e2ncer de ov\u00e1rio resistente - Portal Amazonas 9<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.portalam9.com.br\/?p=3449\" \/>\n<meta property=\"og:locale\" content=\"pt_BR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novo medicamento aprovado pela Anvisa revoluciona tratamento do c\u00e2ncer de ov\u00e1rio resistente - Portal Amazonas 9\" \/>\n<meta property=\"og:description\" content=\"Mirvetuximabe soravtansina mostra ganho em sobrevida global e oferece esperan\u00e7a in\u00e9dita para pacientes no Brasil\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.portalam9.com.br\/?p=3449\" \/>\n<meta property=\"og:site_name\" content=\"Portal Amazonas 9\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-03T16:13:58+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-03T16:14:19+00:00\" \/>\n<meta name=\"author\" content=\"Reda\u00e7\u00e3o Portal AM9\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Reda\u00e7\u00e3o Portal AM9\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. tempo de leitura\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.portalam9.com.br\\\/?p=3449#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.portalam9.com.br\\\/?p=3449\"},\"author\":{\"name\":\"Reda\u00e7\u00e3o Portal AM9\",\"@id\":\"https:\\\/\\\/www.portalam9.com.br\\\/#\\\/schema\\\/person\\\/98ef830cc0fc3a08e33cb435efda505a\"},\"headline\":\"Novo medicamento aprovado pela Anvisa revoluciona tratamento do c\u00e2ncer de ov\u00e1rio resistente\",\"datePublished\":\"2025-09-03T16:13:58+00:00\",\"dateModified\":\"2025-09-03T16:14:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.portalam9.com.br\\\/?p=3449\"},\"wordCount\":372,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/www.portalam9.com.br\\\/#\\\/schema\\\/person\\\/98ef830cc0fc3a08e33cb435efda505a\"},\"image\":{\"@id\":\"https:\\\/\\\/www.portalam9.com.br\\\/?p=3449#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.portalam9.com.br\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/cancer-de-ovario.avif\",\"articleSection\":[\"Health\"],\"inLanguage\":\"pt-BR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/www.portalam9.com.br\\\/?p=3449#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.portalam9.com.br\\\/?p=3449\",\"url\":\"https:\\\/\\\/www.portalam9.com.br\\\/?p=3449\",\"name\":\"Novo medicamento aprovado pela Anvisa revoluciona tratamento do c\u00e2ncer de ov\u00e1rio resistente - Portal Amazonas 9\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.portalam9.com.br\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.portalam9.com.br\\\/?p=3449#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.portalam9.com.br\\\/?p=3449#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.portalam9.com.br\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/cancer-de-ovario.avif\",\"datePublished\":\"2025-09-03T16:13:58+00:00\",\"dateModified\":\"2025-09-03T16:14:19+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.portalam9.com.br\\\/?p=3449#breadcrumb\"},\"inLanguage\":\"pt-BR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.portalam9.com.br\\\/?p=3449\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\\\/\\\/www.portalam9.com.br\\\/?p=3449#primaryimage\",\"url\":\"https:\\\/\\\/www.portalam9.com.br\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/cancer-de-ovario.avif\",\"contentUrl\":\"https:\\\/\\\/www.portalam9.com.br\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/cancer-de-ovario.avif\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.portalam9.com.br\\\/?p=3449#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"In\u00edcio\",\"item\":\"https:\\\/\\\/www.portalam9.com.br\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Novo medicamento aprovado pela Anvisa revoluciona tratamento do c\u00e2ncer de ov\u00e1rio resistente\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.portalam9.com.br\\\/#website\",\"url\":\"https:\\\/\\\/www.portalam9.com.br\\\/\",\"name\":\"OV\u00e9rtice Portal\",\"description\":\"Portal de Noticias de Manaus\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.portalam9.com.br\\\/#\\\/schema\\\/person\\\/98ef830cc0fc3a08e33cb435efda505a\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.portalam9.com.br\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"pt-BR\"},{\"@type\":[\"Person\",\"Organization\"],\"@id\":\"https:\\\/\\\/www.portalam9.com.br\\\/#\\\/schema\\\/person\\\/98ef830cc0fc3a08e33cb435efda505a\",\"name\":\"Reda\u00e7\u00e3o Portal AM9\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\\\/\\\/www.portalam9.com.br\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/logo-portalam9.png\",\"url\":\"https:\\\/\\\/www.portalam9.com.br\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/logo-portalam9.png\",\"contentUrl\":\"https:\\\/\\\/www.portalam9.com.br\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/logo-portalam9.png\",\"width\":343,\"height\":112,\"caption\":\"Reda\u00e7\u00e3o Portal AM9\"},\"logo\":{\"@id\":\"https:\\\/\\\/www.portalam9.com.br\\\/wp-content\\\/uploads\\\/2026\\\/11\\\/logo-portalam9.png\"},\"sameAs\":[\"https:\\\/\\\/portalam9.com.br\\\/\"],\"url\":\"https:\\\/\\\/www.portalam9.com.br\\\/?author=3\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Novo medicamento aprovado pela Anvisa revoluciona tratamento do c\u00e2ncer de ov\u00e1rio resistente - Portal Amazonas 9","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.portalam9.com.br\/?p=3449","og_locale":"pt_BR","og_type":"article","og_title":"Novo medicamento aprovado pela Anvisa revoluciona tratamento do c\u00e2ncer de ov\u00e1rio resistente - Portal Amazonas 9","og_description":"Mirvetuximabe soravtansina mostra ganho em sobrevida global e oferece esperan\u00e7a in\u00e9dita para pacientes no Brasil","og_url":"https:\/\/www.portalam9.com.br\/?p=3449","og_site_name":"Portal Amazonas 9","article_published_time":"2025-09-03T16:13:58+00:00","article_modified_time":"2025-09-03T16:14:19+00:00","author":"Reda\u00e7\u00e3o Portal AM9","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"Reda\u00e7\u00e3o Portal AM9","Est. tempo de leitura":"3 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.portalam9.com.br\/?p=3449#article","isPartOf":{"@id":"https:\/\/www.portalam9.com.br\/?p=3449"},"author":{"name":"Reda\u00e7\u00e3o Portal AM9","@id":"https:\/\/www.portalam9.com.br\/#\/schema\/person\/98ef830cc0fc3a08e33cb435efda505a"},"headline":"Novo medicamento aprovado pela Anvisa revoluciona tratamento do c\u00e2ncer de ov\u00e1rio resistente","datePublished":"2025-09-03T16:13:58+00:00","dateModified":"2025-09-03T16:14:19+00:00","mainEntityOfPage":{"@id":"https:\/\/www.portalam9.com.br\/?p=3449"},"wordCount":372,"commentCount":0,"publisher":{"@id":"https:\/\/www.portalam9.com.br\/#\/schema\/person\/98ef830cc0fc3a08e33cb435efda505a"},"image":{"@id":"https:\/\/www.portalam9.com.br\/?p=3449#primaryimage"},"thumbnailUrl":"https:\/\/www.portalam9.com.br\/wp-content\/uploads\/2025\/09\/cancer-de-ovario.avif","articleSection":["Health"],"inLanguage":"pt-BR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.portalam9.com.br\/?p=3449#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.portalam9.com.br\/?p=3449","url":"https:\/\/www.portalam9.com.br\/?p=3449","name":"Novo medicamento aprovado pela Anvisa revoluciona tratamento do c\u00e2ncer de ov\u00e1rio resistente - Portal Amazonas 9","isPartOf":{"@id":"https:\/\/www.portalam9.com.br\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.portalam9.com.br\/?p=3449#primaryimage"},"image":{"@id":"https:\/\/www.portalam9.com.br\/?p=3449#primaryimage"},"thumbnailUrl":"https:\/\/www.portalam9.com.br\/wp-content\/uploads\/2025\/09\/cancer-de-ovario.avif","datePublished":"2025-09-03T16:13:58+00:00","dateModified":"2025-09-03T16:14:19+00:00","breadcrumb":{"@id":"https:\/\/www.portalam9.com.br\/?p=3449#breadcrumb"},"inLanguage":"pt-BR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.portalam9.com.br\/?p=3449"]}]},{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/www.portalam9.com.br\/?p=3449#primaryimage","url":"https:\/\/www.portalam9.com.br\/wp-content\/uploads\/2025\/09\/cancer-de-ovario.avif","contentUrl":"https:\/\/www.portalam9.com.br\/wp-content\/uploads\/2025\/09\/cancer-de-ovario.avif"},{"@type":"BreadcrumbList","@id":"https:\/\/www.portalam9.com.br\/?p=3449#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"In\u00edcio","item":"https:\/\/www.portalam9.com.br\/"},{"@type":"ListItem","position":2,"name":"Novo medicamento aprovado pela Anvisa revoluciona tratamento do c\u00e2ncer de ov\u00e1rio resistente"}]},{"@type":"WebSite","@id":"https:\/\/www.portalam9.com.br\/#website","url":"https:\/\/www.portalam9.com.br\/","name":"OV\u00e9rtice Portal","description":"Portal de Noticias de Manaus","publisher":{"@id":"https:\/\/www.portalam9.com.br\/#\/schema\/person\/98ef830cc0fc3a08e33cb435efda505a"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.portalam9.com.br\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"pt-BR"},{"@type":["Person","Organization"],"@id":"https:\/\/www.portalam9.com.br\/#\/schema\/person\/98ef830cc0fc3a08e33cb435efda505a","name":"Reda\u00e7\u00e3o Portal AM9","image":{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/www.portalam9.com.br\/wp-content\/uploads\/2026\/11\/logo-portalam9.png","url":"https:\/\/www.portalam9.com.br\/wp-content\/uploads\/2026\/11\/logo-portalam9.png","contentUrl":"https:\/\/www.portalam9.com.br\/wp-content\/uploads\/2026\/11\/logo-portalam9.png","width":343,"height":112,"caption":"Reda\u00e7\u00e3o Portal AM9"},"logo":{"@id":"https:\/\/www.portalam9.com.br\/wp-content\/uploads\/2026\/11\/logo-portalam9.png"},"sameAs":["https:\/\/portalam9.com.br\/"],"url":"https:\/\/www.portalam9.com.br\/?author=3"}]}},"_links":{"self":[{"href":"https:\/\/www.portalam9.com.br\/index.php?rest_route=\/wp\/v2\/posts\/3449","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.portalam9.com.br\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.portalam9.com.br\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.portalam9.com.br\/index.php?rest_route=\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.portalam9.com.br\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3449"}],"version-history":[{"count":1,"href":"https:\/\/www.portalam9.com.br\/index.php?rest_route=\/wp\/v2\/posts\/3449\/revisions"}],"predecessor-version":[{"id":3451,"href":"https:\/\/www.portalam9.com.br\/index.php?rest_route=\/wp\/v2\/posts\/3449\/revisions\/3451"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.portalam9.com.br\/index.php?rest_route=\/wp\/v2\/media\/3450"}],"wp:attachment":[{"href":"https:\/\/www.portalam9.com.br\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3449"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.portalam9.com.br\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3449"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.portalam9.com.br\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3449"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}